A new phase 3 trial has found that mirabegron, a beta-3-adrenoceptor agonist, given once daily for 12 weeks reduced the frequency of incontinence episodes and number of daily urinations in adults with overactive bladder compared to with patients in a placebo group.

Continue Reading

The researchers also found that the incidence of commonly experienced adverse events was similar in the mirabegron and placebo groups. John Schieszer has the story in today’s Medical Minute.